gamma-aminobutyric acid has been researched along with Abnormalities, Congenital in 2 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Gabapentin is currently FDA-approved for treating RLS and preliminary results have shown it may be effective for treating the most severe form of NVP, hyperemesis gravidarum (HG)." | 8.90 | Potential maternal symptomatic benefit of gabapentin and review of its safety in pregnancy. ( Guttuso, T; Shaman, M; Thornburg, LL, 2014) |
| " If future pregnancy registry data confirm this positive safety profile, gabapentin therapy would likely be a safe and effective treatment for RLS during pregnancy." | 6.50 | Potential maternal symptomatic benefit of gabapentin and review of its safety in pregnancy. ( Guttuso, T; Shaman, M; Thornburg, LL, 2014) |
| " Gabapentin is currently FDA-approved for treating RLS and preliminary results have shown it may be effective for treating the most severe form of NVP, hyperemesis gravidarum (HG)." | 4.90 | Potential maternal symptomatic benefit of gabapentin and review of its safety in pregnancy. ( Guttuso, T; Shaman, M; Thornburg, LL, 2014) |
| "A total of 60 pregnant mice, divided into 12 groups of five mice each, were exposed to gabapentin in four different doses of 0 (control), 113, 226, or 452 mg/kg body weight per day, at three different gestational stages including early gestation (1-6 days), mid-gestation (7-12 days), and late gestation (13-17 days)." | 3.74 | Teratogenic effects of the anticonvulsant gabapentin in mice. ( Goel, RK; Madhyastha, S; Nasar, MA; Pai, MM; Prabhu, LV; Rai, R; Singh, G; Yadav, SK, 2008) |
| "We aim to study and elucidate the safety profile of the antiepileptic doses of gabapentin during pregnancy, and to evaluate gabapentin-induced murine fetotoxicity at different dose levels." | 3.74 | Teratogenic effects of the anticonvulsant gabapentin in mice. ( Goel, RK; Madhyastha, S; Nasar, MA; Pai, MM; Prabhu, LV; Rai, R; Singh, G; Yadav, SK, 2008) |
| "Gabapentin should not be prescribed during pregnancy, as no therapeutic dose of gabapentin is safe during this period as far as the foetal well-being is concerned." | 3.74 | Teratogenic effects of the anticonvulsant gabapentin in mice. ( Goel, RK; Madhyastha, S; Nasar, MA; Pai, MM; Prabhu, LV; Rai, R; Singh, G; Yadav, SK, 2008) |
| " If future pregnancy registry data confirm this positive safety profile, gabapentin therapy would likely be a safe and effective treatment for RLS during pregnancy." | 2.50 | Potential maternal symptomatic benefit of gabapentin and review of its safety in pregnancy. ( Guttuso, T; Shaman, M; Thornburg, LL, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guttuso, T | 1 |
| Shaman, M | 1 |
| Thornburg, LL | 1 |
| Prabhu, LV | 1 |
| Rai, R | 1 |
| Pai, MM | 1 |
| Yadav, SK | 1 |
| Madhyastha, S | 1 |
| Goel, RK | 1 |
| Singh, G | 1 |
| Nasar, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "Determining the Effect of an Alternate Recovery Protocol Versus Current Standard of Care After Cesarean Section"[NCT03330119] | Phase 3 | 1,494 participants (Actual) | Interventional | 2017-10-04 | Terminated (stopped due to Lack of Funding/ Resident in charge graduated) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"total narcotic utilization measured with Morphine Milligram Equivalent (MME)~The conversion scale being used will be the Center for Disease Control and Prevention Morphine Equivalent Score.~Lower scores represent less opioid use and a better outcome. Higher scores represent more opioid use and a worse outcome." (NCT03330119)
Timeframe: From time of consent until hospital discharge (3 days)
| Intervention | MME (Mean) |
|---|---|
| Alternate Management | 33.3 |
| Control | 47.2 |
1 review available for gamma-aminobutyric acid and Abnormalities, Congenital
| Article | Year |
|---|---|
Potential maternal symptomatic benefit of gabapentin and review of its safety in pregnancy.
Topics: Amines; Anticonvulsants; Birth Weight; Congenital Abnormalities; Cyclohexanecarboxylic Acids; Female | 2014 |
1 other study available for gamma-aminobutyric acid and Abnormalities, Congenital
| Article | Year |
|---|---|
Teratogenic effects of the anticonvulsant gabapentin in mice.
Topics: Abnormalities, Drug-Induced; Amines; Animals; Anticonvulsants; Body Weight; Congenital Abnormalities | 2008 |